West Oak Capital LLC Purchases 2,564 Shares of Pfizer Inc. (NYSE:PFE)

West Oak Capital LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 13.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 20,950 shares of the biopharmaceutical company’s stock after acquiring an additional 2,564 shares during the quarter. West Oak Capital LLC’s holdings in Pfizer were worth $601,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in PFE. Front Street Capital Management Inc. grew its stake in Pfizer by 4.3% in the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after acquiring an additional 215 shares during the period. Graves Light Lenhart Wealth Inc. boosted its stake in shares of Pfizer by 1.4% during the second quarter. Graves Light Lenhart Wealth Inc. now owns 19,863 shares of the biopharmaceutical company’s stock valued at $729,000 after purchasing an additional 281 shares during the period. Infrastructure Capital Advisors LLC lifted its holdings in shares of Pfizer by 5.2% during the second quarter. Infrastructure Capital Advisors LLC now owns 5,751 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 284 shares in the last quarter. Castleview Partners LLC increased its holdings in Pfizer by 2.4% in the 1st quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 287 shares during the last quarter. Finally, United Bank grew its stake in Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after purchasing an additional 290 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of several recent analyst reports. UBS Group decreased their target price on Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research note on Thursday, December 14th. Truist Financial decreased their target price on Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, December 14th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Barclays dropped their price objective on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a research note on Thursday, December 14th. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research note on Thursday, January 4th. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Price Performance

NYSE PFE traded up $0.09 on Thursday, reaching $27.87. The company had a trading volume of 8,958,670 shares, compared to its average volume of 43,314,059. The firm’s 50 day moving average price is $27.47 and its 200 day moving average price is $29.47. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $157.81 billion, a PE ratio of 77.47, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61. Pfizer Inc. has a 12 month low of $25.61 and a 12 month high of $42.22.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.14 earnings per share. As a group, equities analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.